Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. - Wikidata - wikimedia - TriplyDB

Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.

Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.

http://www.wikidata.org/entity/Q41894332

about

Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial)Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia.Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction.Statins stimulate the production of a soluble form of the receptor for advanced glycation end products.Dietary advanced glycated end-products and medicines influence the expression of SIRT1 and DDOST in peripheral mononuclear cells from long-term type 1 diabetes patients.Combined incubation of platelets and endothelial cells with glycated albumin: Altered thrombogenic and inflammatory responses.Efficacy of Subgingivally Delivered 1.2% Atorvastatin in the Treatment of Chronic Periodontitis in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial.

P2860

Q28731029-03C06B08-EE7F-4702-8091-A92CB54DE1BC Q34269548-54303CE9-2091-4531-A84E-338BF5EEA0FC Q35132249-F180D9D3-1DD9-4D64-9976-6BF1443D87AB Q37267563-99D92B8D-CD70-4D9E-841C-D73E1040CA09 Q37305013-F629F179-FFA2-4AA3-919B-45A965A4CB72 Q38118993-1BC63C34-664A-4945-B7A7-6AB2191A53DE Q39106836-B318746E-76B7-4366-98B1-908F38A9420D Q47658532-C7E95C87-9204-475F-975C-CB86C1BD185F Q53552747-1A0F9561-1775-4C70-86A2-340642ECC267 Q53562629-CBF4AE71-FDC7-4879-8712-739BB36433D9

P2860

Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.

http://www.wikidata.org/entity/Q41894332

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Atorvastatin exerts its anti-a ...... vanced glycation end products.

@en

type

label

Atorvastatin exerts its anti-a ...... vanced glycation end products.

@en

prefLabel

Atorvastatin exerts its anti-a ...... vanced glycation end products.

@en

P1433

Q41894332-96742C94-C5F0-4E76-BE38-BA9031825F27

P1476

Q41894332-B6807D82-FCE1-4EB7-BFAE-1CFA5D424AB6

P2093

Q41894332-08B181F1-05F1-465E-92F9-A9BC68EC1A1E

Q41894332-13C34EA8-ABDD-4D60-ACAE-C72C18DC636B

Q41894332-2E41BD5B-0E4B-44E8-A8EB-C56BF0536C3D

Q41894332-596F17BC-5A7E-49F6-8E61-F65D8314B53B

Q41894332-B9857AE1-B0D5-4668-A687-39F159DF99C6

Q41894332-D57E7B8D-E5D8-4633-A7FF-634BCC1E7C57

Q41894332-E4DA4957-6A94-4F8C-B3E0-B726B15B0EAC

P2860

Q41894332-035ACE9C-27A6-4D25-A15E-8F48255EE3E4

Q41894332-077B84B5-74A4-4D7B-863B-0CB5DB725949

Q41894332-078C67E6-0E64-44B6-AA72-7781AA2E0BAB

Q41894332-0827E151-F1C9-4FAF-8E23-FE26735F3422

Q41894332-09732F0F-DCCC-4C54-99BB-BF8602D81225

Q41894332-0BF406C2-2C66-4256-A290-5CA50C1744AE

Q41894332-11F5EA69-9803-4D78-A4C9-A3DD4B8010D2

Q41894332-12C1849E-5CD4-4C09-B80C-0D8130D5681D

Q41894332-1A3AD4B0-ED4E-4BFE-8385-CDBA6ED7AF6C

Q41894332-2B6FF270-CCC3-4275-BCFD-60D6A67CA9B3

P304

Q41894332-7EECC9B6-8A77-4A41-8AF0-9B8575057E88

P31

Q41894332-182ACAD0-10C6-4B13-9AD6-D1D024F1F887

P356

Q41894332-2708EE90-C0F3-4319-B316-B7F09070E49D

P433

Q41894332-29D041B9-A61F-416A-BFFB-39881CC1B12F

P478

Q41894332-DD93F99E-60D6-4348-8BB0-F64EAAC1E738

P577

Q41894332-D1467A3B-859D-4E23-B92E-E042A8CBF88A

P5875

Q41894332-F0FB9186-9F82-449E-AA43-288503A04B1C

P698

Q41894332-AF7887F2-BBBC-495E-A800-E2629C47EA75

P921

Q41894332-5CCDBC69-5560-4D12-90CE-619F142BFB25

P932

Q41894332-2513026B-417B-4B75-A2E9-F620BA90E78D

P356

J.BBADIS.2011.05.007

P1433

Biochimica et Biophysica Acta

P1476

Atorvastatin exerts its anti-a ...... vanced glycation end products.

@en

P2093

Bo Feng

http://www.w3.org/2001/XMLSchema#string

Fengjing Liu

http://www.w3.org/2001/XMLSchema#string

Hua Wang

http://www.w3.org/2001/XMLSchema#string

Ji-Fan Hu

http://www.w3.org/2001/XMLSchema#string

Junli Xue

http://www.w3.org/2001/XMLSchema#string

Lei Xu

http://www.w3.org/2001/XMLSchema#string

Xinfeng Yan

http://www.w3.org/2001/XMLSchema#string

P2860

The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)

The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells.

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.

Receptors for proteins modified by advanced glycation endproducts (AGE)--their functional role in atherosclerosis.

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

The role of oxidative stress and NF-kappaB activation in late diabetic complications.

P304

1130-1137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBADIS.2011.05.007

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

1812

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51200556

http://www.w3.org/2001/XMLSchema#string

P698

21651980

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

3143240

http://www.w3.org/2001/XMLSchema#string